首页> 外文期刊>Theranostics >Amplification-driven BCL6-suppressed cytostasis is mediated by transrepression of FOXO3 and post-translational modifications of FOXO3 in urinary bladder urothelial carcinoma
【24h】

Amplification-driven BCL6-suppressed cytostasis is mediated by transrepression of FOXO3 and post-translational modifications of FOXO3 in urinary bladder urothelial carcinoma

机译:扩增驱动的BCL6-抑制的细胞质是通过FOXO3的转氧基传递和FoxO3在膀胱尿路上皮癌中的翻译后修饰介导的

获取原文
           

摘要

Muscle-invasive urinary bladder urothelial carcinoma (UBUC) is a lethal disease for which effective prognostic markers and potential therapy targets are still lacking. Previous array comparative genomic hybridization identified that 3q27 is frequently amplified in muscle-invasive UBUCs, one candidate proto-oncogene, B-cell CLL/lymphoma 6 (BCL6), mapped to this region. We therefore aimed to explore its downstream targets and physiological roles in UBUC progression. Methods: Specimens from UBUC patients, NOD/SCID mice and several UBUC-derived cell lines were used to perform quantitative RT-PCR, fluorescence in situ hybridization immunohistochemistry, xenograft, gene stable overexpression/knockdown and a series of in vitro experiments. Results: Amplification of the BCL6 gene lead to upregulation of BCL6 mRNA and protein levels in a substantial set of advanced UBUCs. High BCL6 protein level significantly predicted poor disease-specific and metastasis-free survivals. Knockdown of the BCL6 gene in J82 cells inhibited tumor growth and enhanced apoptosis in the NOD/SCID xenograft model. In vitro experiments demonstrated that BCL6 inhibited cytostasis, induced cell migration, invasion along with alteration of the expression levels of several related regulators. At molecular level, BCL6 inhibited forkhead box O3 (FOXO3) transcription, subsequent translation and upregulation of phosphorylated/inactive FOXO3 through phosphoinositide 3-kinase (PI3K)/AKT serine/threonine kinase (AKT) and/or epidermal growth factor receptor (EGFR)/mitogen-activated protein kinase 1/2 (MAP2K1/2) signaling pathway(s). Two BCL6 binding sites on the proximal promoter region of the FOXO3 gene were confirmed. Conclusion: Overexpression of BCL6 served a poor prognostic factor in UBUC patients. In vivo and in vitro studies suggested that BCL6 functions as an oncogene through direct transrepression of the FOXO3 gene, downregulation and phosphorylation of the FOXO3 protein.? The author(s).
机译:肌肉侵袭性膀胱尿路上皮癌(UBUC)是一种致命疾病,其仍然缺乏有效的预后标记和潜在治疗目标。先前的阵列对比基因组杂交鉴定为肌肉侵袭性Ubuc经常扩增3Q27,映射到该区域的候选原癌基因,一种候选原癌基因,B细胞CLL /淋巴瘤6(BCL6)。因此,我们旨在探讨Ubuc进展中的下游目标和生理作用。方法:来自UBUC患者的标本,NOD / SCID小鼠和几种UBUC衍生的细胞系用于进行定量RT-PCR,荧光原位杂交免疫组化,异种移植物,基因稳定的过表达/敲低和一系列体外实验。结果:BCL6基因的扩增导致大量高级Ubuc中的Bcl6 mRNA和蛋白质水平的上调。高BCL6蛋白质水平显着预测疾病特异性和无转移的幸存者。 J82细胞中BCL6基因的敲低抑制了NOD / SCID异种移植模型中的肿瘤生长和增强的凋亡。体外实验证明,BCL6抑制细胞质,诱导细胞迁移,侵袭以及若干相关调节剂的表达水平的改变。在分子水平,BCl6抑制尖头箱O3(FOXO3)转录,随后通过磷酸膦酸酯3-激酶(PI3K)/ AKT丝氨酸/苏氨酸激酶(AKT)和/或表皮生长因子受体(EGFR)的磷酸化/无活性FOXO3的翻译和上调/丝裂原活化蛋白激酶1/2(MAP2K1 / 2)信号通路。确认了FoxO3基因的近端启动子区域上的两个Bcl6结合位点。结论:BCL6的过度表达在UBUC患者的预后差。体内和体外研究表明,BCL6通过FoxO3基因的直接转换,下调和FoxO3蛋白的磷酸化用作癌基因。作者。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号